NanoRepro - 股票

NanoRepro 负债 2024

NanoRepro 负债

2.04 百万 EUR

股票代码

NN6.DE

ISIN

DE0006577109

WKN

657710

在2024年,NanoRepro的负债总额为2.04 百万 EUR,与上一年21.54 百万 EUR负债相比,差异为-90.53%

NanoRepro Aktienanalyse

NanoRepro在做什么?

The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro ist eines der beliebtesten Unternehmen auf Eulerpool.com.

负债的详细信息

NanoRepro的负债评估

NanoRepro的负债包括公司对外界各方和投资者的财务承诺和债务。它们分为短期负债,即一年内到期的负债,和长期负债,即在较长时间段内到期的负债。对这些负债的详细评估对于评价NanoRepro的财务稳定性、运营效率和长期可持续性至关重要。

年度对比

通过对NanoRepro的负债进行年度对比,投资者可以识别公司财务定位的趋势、变化和异常。负债总额的减少通常表明财务状况的强化,而增加则可能表明投资、收购的增加或可能的财务压力。

对投资的影响

NanoRepro的总负债在决定公司的杠杆作用和风险状况方面起到重要作用。投资者和分析师会仔细研究这个方面,以判断公司满足其财务承诺的能力,这将影响投资吸引力和信用评级。

负债波动的解读

NanoRepro的负债结构变化反映了其财务管理和战略的变化。负债的减少反映了高效的财务管理或债务偿还,而增加则可能表明扩张、收购行动或运营成本的增加,这些都会对投资者产生不同的影响。

关于NanoRepro股票的常见问题

NanoRepro今年的负债有多高?

NanoRepro今年的负债额为2.04 百万 EUR。

NanoRepro的负债与去年相比高了多少?

NanoRepro的负债与去年相比,增加了-90.53% 下降了。

NanoRepro的投资者面临高负债的后果是什么?

对于NanoRepro的投资者来说,高额债务可能构成风险,因为它会使公司的财务状况变弱,可能会影响其履行责任的能力。

NanoRepro的投资者面临低负债率会有什么后果?

低债务意味着NanoRepro具有强大的财务地位,并且能够履行其义务,而不会过度负担其财务。

NanoRepro的负债增加会对公司产生什么影响?

NanoRepro的负债增加可能导致公司的义务增加,并可能更难以履行其财务责任。

NanoRepro的负债减少会对公司产生什么影响?

NanoRepro的负债减少可能意味着公司的负担较轻,并且拥有更强大的财务地位,这将使其更容易履行其财务义务。

是什么因素影响了NanoRepro的负债?

一些可能影响NanoRepro负债的因素包括投资、收购、运营成本和营业收入的发展。

NanoRepro的负债总额为何对投资者如此重要?

NanoRepro的负债对投资者来说很重要,因为它们是公司财务稳定性的指标,且能向投资者提供关于公司如何履行其财务义务的信息。

NanoRepro可以采取哪些战略措施来改变负债?

为了改变负债状况,NanoRepro可以采取的措施包括节约成本、提高销售额、出售资产、获得投资或建立合作伙伴关系等。企业进行全面的财务状况审查以选择最佳的战略措施是非常重要的。

NanoRepro支付多少股息?

在过去的12个月中,NanoRepro支付了0.5 EUR 的股息。这相当于大约29.5 %的股息收益率。在未来的12个月内,NanoRepro预计将支付0.5 EUR的股息。

NanoRepro的股息收益率有多高?

NanoRepro当前的股息收益率为29.5 %。

NanoRepro什么时候支付股息?

NanoRepro按季度支付股息。这些股息将在月份分发。

NanoRepro的股息有多安全?

NanoRepro 在过去1年里每年都支付了股息。

NanoRepro的股息有多高?

预计未来12个月的股息将达到0.5 EUR。这相当于29.5 %的股息收益率。

NanoRepro位于哪个行业?

NanoRepro 被分配到“健康”板块。

Wann musste ich die Aktien von NanoRepro kaufen, um die vorherige Dividende zu erhalten?

要获得NanoRepro在支付的0.15 EUR的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

NanoRepro最后一次支付股息是什么时候?

上一次股息发放日期为。

NanoRepro在2023年的股息是多少?

在2023年,NanoRepro 分配了0 EUR作为股息。

NanoRepro 的股息是以哪种货币支付的?

NanoRepro的股息将以EUR的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

NanoRepro 股票在以下供应商处可进行定投计划:ING

Andere Kennzahlen von NanoRepro

我们对NanoRepro 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和NanoRepro 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: